Commonwealth Equity Services LLC Lowers Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Commonwealth Equity Services LLC decreased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.1% during the fourth quarter, Holdings Channel reports. The institutional investor owned 18,014 shares of the biopharmaceutical company’s stock after selling 967 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Regeneron Pharmaceuticals were worth $12,832,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently modified their holdings of REGN. GSA Capital Partners LLP purchased a new stake in shares of Regeneron Pharmaceuticals in the third quarter worth about $665,000. Empowered Funds LLC raised its holdings in Regeneron Pharmaceuticals by 7.1% in the 3rd quarter. Empowered Funds LLC now owns 1,652 shares of the biopharmaceutical company’s stock worth $1,737,000 after purchasing an additional 109 shares during the period. Claro Advisors LLC raised its holdings in Regeneron Pharmaceuticals by 110.6% in the 3rd quarter. Claro Advisors LLC now owns 478 shares of the biopharmaceutical company’s stock worth $502,000 after purchasing an additional 251 shares during the period. Thrivent Financial for Lutherans raised its holdings in Regeneron Pharmaceuticals by 16.7% in the 3rd quarter. Thrivent Financial for Lutherans now owns 9,120 shares of the biopharmaceutical company’s stock worth $9,587,000 after purchasing an additional 1,306 shares during the period. Finally, AMG National Trust Bank raised its holdings in Regeneron Pharmaceuticals by 14.6% in the 3rd quarter. AMG National Trust Bank now owns 220 shares of the biopharmaceutical company’s stock worth $231,000 after purchasing an additional 28 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on REGN. Bank of America reaffirmed an “underperform” rating and issued a $565.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. Canaccord Genuity Group began coverage on Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target for the company. Truist Financial reduced their price target on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. Leerink Partners raised Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their target price for the company from $762.00 to $834.00 in a report on Wednesday, February 5th. Finally, Wells Fargo & Company reduced their target price on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a report on Friday, January 10th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Trading Down 2.0 %

Shares of Regeneron Pharmaceuticals stock opened at $664.96 on Wednesday. The firm has a market capitalization of $72.70 billion, a price-to-earnings ratio of 17.37, a PEG ratio of 2.34 and a beta of 0.27. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $642.00 and a fifty-two week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The stock has a 50 day moving average of $692.84 and a 200 day moving average of $823.99.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the prior year, the business posted $11.86 earnings per share. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be given a dividend of $0.88 per share. The ex-dividend date is Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.53%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.